EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.

Stefano Cafarotti, Alfredo Cesario, Filippo Lococo, Stefano Margaritora, Pierluigi Granone

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

84 Citazioni (Scopus)


The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.
Lingua originaleEnglish
pagine (da-a)320-330
Numero di pagine11
RivistaInternational Journal of Medical Sciences
Stato di pubblicazionePubblicato - 2013


  • EGFR targeted therapy, NSCLC, TKIs, advanced, mutation, resistance


Entra nei temi di ricerca di 'EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.'. Insieme formano una fingerprint unica.

Cita questo